Basilea Pharmaceutica（PK5）株式概要Basilea Pharmaceutica AGは、スイスの商業段階のバイオテクノロジー企業で、重篤な細菌・真菌感染症の治療薬の開発・商業化に注力している。 詳細PK5 ファンダメンタル分析スノーフレーク・スコア評価5/6将来の成長1/6過去の実績3/6財務の健全性6/6配当金0/6報酬当社が推定した公正価値より38.7%で取引されている 収益は年間4.87%増加すると予測されています 同業他社や業界と比較して、良好な取引価格 リスク分析利益率(17.3%)は昨年より低い(37.2%) すべてのリスクチェックを見るPK5 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW476,935 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA476,935 investors already sharing narrativesYour Fair Value€Current Price€56.0044.6% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-62m232m2016201920222025202620282031Revenue CHF 212.0mEarnings CHF 36.7mAdvancedSet Fair ValueView all narrativesBasilea Pharmaceutica AG 競合他社2investSymbol: XTRA:2INVMarket cap: €62.9mNovogeniaSymbol: MUN:7V0Market cap: €72.0m2investSymbol: DB:2INVMarket cap: €45.1mDermapharm HoldingSymbol: XTRA:DMPMarket cap: €2.0b価格と性能株価の高値、安値、推移の概要Basilea Pharmaceutica過去の株価現在の株価CHF 56.0052週高値CHF 63.7052週安値CHF 48.15ベータ0.411ヶ月の変化3.13%3ヶ月変化-6.51%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-15.79%最新ニュースお知らせ • Aug 06Basilea Pharmaceutica Ltd Receives Additional Funding to Continue Development of Novel Antibiotic Ceftibuten-Ledaborbactam EtzadroxilBasilea Pharmaceutica Ltd. has been awarded an additional USD 5.4 million of funding by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, to continue the development of the novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. After this additional funding of USD 5.4 million, a total of USD 30.8 million of funding has been awarded to Basilea by BARDA. The contract has the potential to provide a total of up to USD 172 million of non-dilutive funding, of which approximately USD 14 million relate to the period prior to novation of the contract to Basilea. Many Gram-negative bacteria express enzymes such as extended spectrum beta-lactamases (ESBL) that confer resistance against commonly used antibiotics. Beta-lactamase inhibitors block these enzymes and restore the activity of beta-lactam antibiotics against initially resistant Gram-negative bacteria, therefore BL/BLI combinations are an important addition to the armamentarium for the treatment of infections caused by multidrug-resistant bacterial pathogens. Ledaborbactam etzadroxil is the orally bioavailable prodrug of ledaborbactam, a novel broad-spectrum boronic acid beta-lactamase inhibitor, which is being developed in combination with ceftibuten, an oral cephalosporin antibiotic, which is approved in the US for the treatment of upper and lower respiratory tract infections and for urinary tract infections outside the US. In vitro and in vivo studies demonstrated that ledaborbactam etzadroxil restores the activity of ceftibuten against strains of Enterobacterales expressing Ambler class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and class A and D carbapenemases (KPC and OXA-48, respectively) as well as multidrug-resistant (MDR) Enterobacterales. Ceftibuten-ledaborbactam etzadroxil has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the US Food and Drug Administration (FDA) for cUTI and uncomplicated urinary tract infections. Ceftibuten-ledaborbactam etzadroxil is an investigational drug and is not yet approved in any country for commercial use. Complicated UTIs, which include pyelonephritis (kidney infections), are defined as urinary tract infections ascending from the bladder accompanied by local and systemic signs and symptoms and are one of the most common bacterial infections in hospital and community settings. Increasing resistance of bacteria causing complicated urinary tract infections has led to limited availability of effective oral antibiotic treatment options. Currently, there are no approved oral beta-lactam or beta-lactam/beta-lactamase inhibitor combinations that are effective against Enterobacterales expressing Ambler class A ESBLs, class C cephalosporinases, and class A & D serine carbapenemases (KPC and OXA-48).お知らせ • Jul 29Basilea Receives USD 30 Million Funding Under Existing BARDA Agreement for Advancing Phase 3 Development of Novel Antifungal FosmanogepixBasilea Pharmaceutica Ltd, Allschwil announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), awarded USD 30 million in additional funding to Basilea after meeting its prespecified enrollment milestone. The additional funding will continue to advance Basilea’s ongoing phase 3 program for the novel antifungal, fosmanogepix. The commitment is made under the “Other Transaction Agreement” (OTA, agreement number 75A50124C00033). The new tranche of USD 30 million comes in addition to the USD 93 million already committed by BARDA since the signing of the OTA in September 2024. BARDA’s financial contribution is about 60% of the total costs of the supported projects, fosmanogepix and BAL2062, including clinical and regulatory activities, over the term of the OTA, which could provide a total potential non-dilutive funding of up to approximately USD 268 million over up to 12 years, if all additional options to extend the contract are exercised by BARDA. Fosmanogepix is a first-in-class clinical-stage broad-spectrum antifungal. It has a novel mechanism of action and its active moiety has shown activity against common species of Candida and Aspergillus, including multi-drug-resistant strains, such as Candida auris and Candida glabrata, as well as rare difficult-to-treat molds including Fusarium spp., Scedosporium spp., and some fungi from the Mucorales order. Fosmanogepix intravenous and oral formulations have been evaluated in clinical phase 2 studies for the treatment of patients with Candidemia, including Candida auris infections, and invasive mold infections. The FAST study, a phase 3 study evaluating fosmanogepix in the treatment of adult patients with candidemia and/or invasive candidiasis and the FORWARD study, a phase 3 study, in the treatment of adult patients with invasive mold infections, are ongoing. Fosmanogepix has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration for a number of indications, and is designated as a Qualified Infectious Disease Product (QIDP). BAL2062 is a first-in-class clinical-stage antifungal, derived from a natural product, and has demonstrated fungicidal activity against clinically important molds such as Aspergillus spp., including azole-resistant strains. Safety and tolerability have been demonstrated in a previously completed phase 1 study with single and multiple ascending intravenous (i.v.) doses. The drug candidate has Qualified Infectious Disease Product (QIDP), Orphan Drug and Fast Track designation from the US Food and Drug Administration (FDA) for invasive aspergillosis.お知らせ • May 28Basilea Pharmaceutica Ltd Receives Additional USD 13.3 Million From BARDA To Continue Development Of Novel Antibiotic Ceftibuten-Ledaborbactam EtzadroxilBasilea Pharmaceutica Ltd, Allschwil announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, awarded USD 13.3 million to Basilea to continue the development of Basilea’s novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. After the current tranche of USD 13.3 million, a total of USD 25 million have been committed by BARDA. The contract could provide up to USD 133 million of additional non-dilutive funding. Many Gram-negative bacteria express enzymes such as extended spectrum beta-lactamases (ESBL) that confer resistance against commonly used antibiotics. Beta-lactamase inhibitors block these enzymes and restore the activity of beta-lactam antibiotics against initially resistant Gram-negative bacteria, therefore BL/BLI combinations are an important addition to the armamentarium for the treatment of infections caused by multidrug-resistant bacterial pathogens. Ledaborbactam etzadroxil is the orally bioavailable prodrug of ledaborbactam, a novel broad-spectrum boronic acid beta-lactamase inhibitor, which is being developed in combination with ceftibuten, an oral cephalosporin antibiotic, which is approved in the US for the treatment of upper and lower respiratory tract infections and for urinary tract infections outside the US. In vitro and in vivo studies demonstrated that ledaborbactam etzadroxil restores the activity of ceftibuten against strains of Enterobacterales expressing Ambler class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and class A and D carbapenemases (KPC and OXA-48, respectively) as well as multidrug-resistant (MDR) Enterobacterales. Ceftibuten-ledaborbactam etzadroxil has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the US Food and Drug Administration (FDA) for cUTI and uncomplicated urinary tract infections. Ceftibuten-ledaborbactam etzadroxil is an investigational drug and is not yet approved in any country for commercial use. Complicated UTIs, which include pyelonephritis (kidney infections), are defined as urinary tract infections ascending from the bladder accompanied by local and systemic signs and symptoms and are one of the most common bacterial infections in hospital and community settings. Increasing resistance of bacteria causing complicated urinary tract infections has led to limited availability of effective oral antibiotic treatment options. Currently, there are no approved oral beta-lactam or beta-lactam/beta-lactamase inhibitor combinations that are effective against Enterobacterales expressing Ambler class A ESBLs, class C cephalosporinases, and class A & D serine carbapenemases (KPC and OXA-48).お知らせ • Apr 27Basilea Pharmaceutica AG to Report First Half, 2026 Results on Aug 18, 2026Basilea Pharmaceutica AG announced that they will report first half, 2026 results on Aug 18, 2026お知らせ • Apr 17Basilea Pharmaceutica AG Approves Board and Committee AppointmentsBasilea Pharmaceutica Ltd. at its annual general meeting held on April 15, 2026, approved election of Dr. Naseem Amin and Ms. Anne Whitaker as new members of the board of directors. In addition, Mr. Kruimer, Dr. Onetto and Ms. Anne Whitaker were appointed as members of the compensation committee. The term of all board members lasts until the AGM 2027.お知らせ • Apr 11Basilea Pharmaceutica Ltd Announces Additional Funding for Clinical Development of Antibiotic BAL2420Basilea Pharmaceutica Ltd, Allschwil announced that it was awarded an additional USD 6 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products. The additional non-dilutive funding will support the first-in-human phase 1 clinical study of Basilea’s novel antibiotic BAL2420 (LptA inhibitor) and related activities. The phase 1 study has already been initiated, with the first subject dosed in March 2026. BAL2420 belongs to one of the very few novel classes of antibiotics in clinical development. It is targeting LptA, which is part of the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. LptA inhibitors have shown potent and rapid bactericidal activity in vitro and in vivo against Gram-negative bacteria of the Enterobacteriaceae family, such as E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin, an antibiotic regarded as last-resort therapy. The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have identified Enterobacteriaceae, including carbapenem-resistant strains, as high priority pathogens for which new and effective antibiotic treatments are urgently needed. CARB-X has supported the development of BAL2420 since 2020, advancing the project from the hit-to-lead stage to the first-in-human study. Research reported in this publication is supported by CARB-X. CARB-X is funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) under agreement number 75A50122C00028 and by awards from Wellcome (WT224842), the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Gates Foundation, Germany’s Federal Ministry of Research, Technology and Space (BMFTR), the Novo Nordisk Foundation, Italy’s Ministry of Economy and Finance (MEF), Japan’s Ministry of Health, the European Commission’s DG Health Emergency Preparedness and Response Authority (DG HERA), and KfW Development Bank. The U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in HHS, provides support in the form of in-kind services through access to a suite of preclinical services for product development. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or its funders.最新情報をもっと見るRecent updatesお知らせ • Aug 06Basilea Pharmaceutica Ltd Receives Additional Funding to Continue Development of Novel Antibiotic Ceftibuten-Ledaborbactam EtzadroxilBasilea Pharmaceutica Ltd. has been awarded an additional USD 5.4 million of funding by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, to continue the development of the novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. After this additional funding of USD 5.4 million, a total of USD 30.8 million of funding has been awarded to Basilea by BARDA. The contract has the potential to provide a total of up to USD 172 million of non-dilutive funding, of which approximately USD 14 million relate to the period prior to novation of the contract to Basilea. Many Gram-negative bacteria express enzymes such as extended spectrum beta-lactamases (ESBL) that confer resistance against commonly used antibiotics. Beta-lactamase inhibitors block these enzymes and restore the activity of beta-lactam antibiotics against initially resistant Gram-negative bacteria, therefore BL/BLI combinations are an important addition to the armamentarium for the treatment of infections caused by multidrug-resistant bacterial pathogens. Ledaborbactam etzadroxil is the orally bioavailable prodrug of ledaborbactam, a novel broad-spectrum boronic acid beta-lactamase inhibitor, which is being developed in combination with ceftibuten, an oral cephalosporin antibiotic, which is approved in the US for the treatment of upper and lower respiratory tract infections and for urinary tract infections outside the US. In vitro and in vivo studies demonstrated that ledaborbactam etzadroxil restores the activity of ceftibuten against strains of Enterobacterales expressing Ambler class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and class A and D carbapenemases (KPC and OXA-48, respectively) as well as multidrug-resistant (MDR) Enterobacterales. Ceftibuten-ledaborbactam etzadroxil has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the US Food and Drug Administration (FDA) for cUTI and uncomplicated urinary tract infections. Ceftibuten-ledaborbactam etzadroxil is an investigational drug and is not yet approved in any country for commercial use. Complicated UTIs, which include pyelonephritis (kidney infections), are defined as urinary tract infections ascending from the bladder accompanied by local and systemic signs and symptoms and are one of the most common bacterial infections in hospital and community settings. Increasing resistance of bacteria causing complicated urinary tract infections has led to limited availability of effective oral antibiotic treatment options. Currently, there are no approved oral beta-lactam or beta-lactam/beta-lactamase inhibitor combinations that are effective against Enterobacterales expressing Ambler class A ESBLs, class C cephalosporinases, and class A & D serine carbapenemases (KPC and OXA-48).お知らせ • Jul 29Basilea Receives USD 30 Million Funding Under Existing BARDA Agreement for Advancing Phase 3 Development of Novel Antifungal FosmanogepixBasilea Pharmaceutica Ltd, Allschwil announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), awarded USD 30 million in additional funding to Basilea after meeting its prespecified enrollment milestone. The additional funding will continue to advance Basilea’s ongoing phase 3 program for the novel antifungal, fosmanogepix. The commitment is made under the “Other Transaction Agreement” (OTA, agreement number 75A50124C00033). The new tranche of USD 30 million comes in addition to the USD 93 million already committed by BARDA since the signing of the OTA in September 2024. BARDA’s financial contribution is about 60% of the total costs of the supported projects, fosmanogepix and BAL2062, including clinical and regulatory activities, over the term of the OTA, which could provide a total potential non-dilutive funding of up to approximately USD 268 million over up to 12 years, if all additional options to extend the contract are exercised by BARDA. Fosmanogepix is a first-in-class clinical-stage broad-spectrum antifungal. It has a novel mechanism of action and its active moiety has shown activity against common species of Candida and Aspergillus, including multi-drug-resistant strains, such as Candida auris and Candida glabrata, as well as rare difficult-to-treat molds including Fusarium spp., Scedosporium spp., and some fungi from the Mucorales order. Fosmanogepix intravenous and oral formulations have been evaluated in clinical phase 2 studies for the treatment of patients with Candidemia, including Candida auris infections, and invasive mold infections. The FAST study, a phase 3 study evaluating fosmanogepix in the treatment of adult patients with candidemia and/or invasive candidiasis and the FORWARD study, a phase 3 study, in the treatment of adult patients with invasive mold infections, are ongoing. Fosmanogepix has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration for a number of indications, and is designated as a Qualified Infectious Disease Product (QIDP). BAL2062 is a first-in-class clinical-stage antifungal, derived from a natural product, and has demonstrated fungicidal activity against clinically important molds such as Aspergillus spp., including azole-resistant strains. Safety and tolerability have been demonstrated in a previously completed phase 1 study with single and multiple ascending intravenous (i.v.) doses. The drug candidate has Qualified Infectious Disease Product (QIDP), Orphan Drug and Fast Track designation from the US Food and Drug Administration (FDA) for invasive aspergillosis.お知らせ • May 28Basilea Pharmaceutica Ltd Receives Additional USD 13.3 Million From BARDA To Continue Development Of Novel Antibiotic Ceftibuten-Ledaborbactam EtzadroxilBasilea Pharmaceutica Ltd, Allschwil announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, awarded USD 13.3 million to Basilea to continue the development of Basilea’s novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. After the current tranche of USD 13.3 million, a total of USD 25 million have been committed by BARDA. The contract could provide up to USD 133 million of additional non-dilutive funding. Many Gram-negative bacteria express enzymes such as extended spectrum beta-lactamases (ESBL) that confer resistance against commonly used antibiotics. Beta-lactamase inhibitors block these enzymes and restore the activity of beta-lactam antibiotics against initially resistant Gram-negative bacteria, therefore BL/BLI combinations are an important addition to the armamentarium for the treatment of infections caused by multidrug-resistant bacterial pathogens. Ledaborbactam etzadroxil is the orally bioavailable prodrug of ledaborbactam, a novel broad-spectrum boronic acid beta-lactamase inhibitor, which is being developed in combination with ceftibuten, an oral cephalosporin antibiotic, which is approved in the US for the treatment of upper and lower respiratory tract infections and for urinary tract infections outside the US. In vitro and in vivo studies demonstrated that ledaborbactam etzadroxil restores the activity of ceftibuten against strains of Enterobacterales expressing Ambler class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and class A and D carbapenemases (KPC and OXA-48, respectively) as well as multidrug-resistant (MDR) Enterobacterales. Ceftibuten-ledaborbactam etzadroxil has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the US Food and Drug Administration (FDA) for cUTI and uncomplicated urinary tract infections. Ceftibuten-ledaborbactam etzadroxil is an investigational drug and is not yet approved in any country for commercial use. Complicated UTIs, which include pyelonephritis (kidney infections), are defined as urinary tract infections ascending from the bladder accompanied by local and systemic signs and symptoms and are one of the most common bacterial infections in hospital and community settings. Increasing resistance of bacteria causing complicated urinary tract infections has led to limited availability of effective oral antibiotic treatment options. Currently, there are no approved oral beta-lactam or beta-lactam/beta-lactamase inhibitor combinations that are effective against Enterobacterales expressing Ambler class A ESBLs, class C cephalosporinases, and class A & D serine carbapenemases (KPC and OXA-48).お知らせ • Apr 27Basilea Pharmaceutica AG to Report First Half, 2026 Results on Aug 18, 2026Basilea Pharmaceutica AG announced that they will report first half, 2026 results on Aug 18, 2026お知らせ • Apr 17Basilea Pharmaceutica AG Approves Board and Committee AppointmentsBasilea Pharmaceutica Ltd. at its annual general meeting held on April 15, 2026, approved election of Dr. Naseem Amin and Ms. Anne Whitaker as new members of the board of directors. In addition, Mr. Kruimer, Dr. Onetto and Ms. Anne Whitaker were appointed as members of the compensation committee. The term of all board members lasts until the AGM 2027.お知らせ • Apr 11Basilea Pharmaceutica Ltd Announces Additional Funding for Clinical Development of Antibiotic BAL2420Basilea Pharmaceutica Ltd, Allschwil announced that it was awarded an additional USD 6 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products. The additional non-dilutive funding will support the first-in-human phase 1 clinical study of Basilea’s novel antibiotic BAL2420 (LptA inhibitor) and related activities. The phase 1 study has already been initiated, with the first subject dosed in March 2026. BAL2420 belongs to one of the very few novel classes of antibiotics in clinical development. It is targeting LptA, which is part of the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. LptA inhibitors have shown potent and rapid bactericidal activity in vitro and in vivo against Gram-negative bacteria of the Enterobacteriaceae family, such as E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin, an antibiotic regarded as last-resort therapy. The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have identified Enterobacteriaceae, including carbapenem-resistant strains, as high priority pathogens for which new and effective antibiotic treatments are urgently needed. CARB-X has supported the development of BAL2420 since 2020, advancing the project from the hit-to-lead stage to the first-in-human study. Research reported in this publication is supported by CARB-X. CARB-X is funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) under agreement number 75A50122C00028 and by awards from Wellcome (WT224842), the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Gates Foundation, Germany’s Federal Ministry of Research, Technology and Space (BMFTR), the Novo Nordisk Foundation, Italy’s Ministry of Economy and Finance (MEF), Japan’s Ministry of Health, the European Commission’s DG Health Emergency Preparedness and Response Authority (DG HERA), and KfW Development Bank. The U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in HHS, provides support in the form of in-kind services through access to a suite of preclinical services for product development. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or its funders.お知らせ • Mar 26Basilea Pharmaceutica AG, Annual General Meeting, Apr 15, 2026Basilea Pharmaceutica AG, Annual General Meeting, Apr 15, 2026, at 14:00 W. Europe Standard Time.お知らせ • Mar 23Basilea Pharmaceutica Ltd Announces Start Of First-In-Human Study Of Novel Antibiotic BAL2420Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced the dosing of the first healthy volunteer in the first-in-human phase 1 study of BAL2420, evaluating the safety, tolerability and pharmacokinetics of this lipopolysaccharide transport protein A (LptA) inhibitor. BAL2420 belongs to a novel class of antibiotics. It targets LptA, which is part of the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. LptA inhibitors have shown potent and rapid bactericidal activity in vitro and in vivo against Gram-negative bacteria of the Enterobacteriaceae family, such as E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin, an antibiotic regarded as last-resort therapy. The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have identified Enterobacteriaceae, including carbapenem-resistant strains, as high priority pathogens for which new and effective antibiotic treatments are urgently needed. This single-center, randomized, dose-escalation, double-blind and placebo-controlled phase 1 study assesses intravenous administration of BAL2420 using a single- and multiple-ascending dose study design. Data from this study will support the further clinical development of BAL2420 as a potential treatment option for serious infections caused by Gram-negative bacteria, including multidrug-resistant bacteria. CARB-X has supported the development of BAL2420 since 2020, advancing the project from the Hit-to-Lead stage to the first-in-human study. CARB-X’s funding for this project is provided by federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842) and Germany’s Federal Ministry of Research, Technology and Space (BMFTR). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders.お知らせ • Feb 18+ 1 more updateBasilea Pharmaceutica AG Provides Earnings Guidance for the Full Year 2026Basilea Pharmaceutica AG provided earnings guidance for the full year 2026. For the year, the company expects total revenue of ~10% increase. Operating profit of ~20% increase.株主還元PK5DE BiotechsDE 市場7D1.1%-0.6%0.2%1Yn/a5.4%3.6%株主還元を見る業界別リターン: PK5がGerman Biotechs業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: PK5 German市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is PK5's price volatile compared to industry and market?PK5 volatilityPK5 Average Weekly Movement3.7%Biotechs Industry Average Movement6.6%Market Average Movement5.2%10% most volatile stocks in DE Market13.0%10% least volatile stocks in DE Market2.7%安定した株価: PK5 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: PK5の 週次ボラティリティ ( 4% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2000189David Veitchwww.basilea.comBasilea Pharmaceutica AGは、スイスの商業段階のバイオテクノロジー企業で、重篤な細菌・真菌感染症の治療薬の開発・商業化に注力している。同社は、侵襲性アスペルギルス症およびムコルミコーシスの治療薬として静脈内投与および経口投与の抗真菌薬Cresemba（イサブコナゾール）、肺炎、黄色ブドウ球菌菌血症（SAB）、急性細菌性皮膚・皮膚構造感染症（ABSSSI）の治療薬として抗生物質Zevtera（セフトビプロール）を提供している。また、侵襲性カビ・酵母感染症治療薬としてフェーズ3段階にある広域抗真菌薬ホスマノゲピクス、複雑性尿路感染症（cUTI）治療薬としてフェーズ3段階にある経口抗生物質セフチブテン・レダボルバクタムなど、臨床段階にある抗感染症パイプラインも有している；BAL2062：侵襲性アスペルギルス症治療薬候補で、現在第2相臨床開発段階にある。BAL2420：重症腸内細菌科感染症をターゲットとする前臨床段階の抗生物質。Basilea Pharmaceutica AGは2000年に設立され、スイスのAllschwilに本社を置いている。もっと見るBasilea Pharmaceutica AG 基礎のまとめBasilea Pharmaceutica の収益と売上を時価総額と比較するとどうか。PK5 基礎統計学時価総額€699.73m収益（TTM）€42.78m売上高(TTM)€247.03m16.4xPER（株価収益率2.8xP/SレシオPK5 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PK5 損益計算書（TTM）収益CHF 232.38m売上原価CHF 145.22m売上総利益CHF 87.16mその他の費用CHF 46.92m収益CHF 40.24m直近の収益報告Dec 31, 2025次回決算日Aug 18, 2026一株当たり利益（EPS）3.25グロス・マージン37.51%純利益率17.32%有利子負債／自己資本比率59.0%PK5 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/16 01:26終値2026/08/14 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Basilea Pharmaceutica AG 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。17 アナリスト機関Brigitte de LimaBofA Global ResearchBrian WhiteCalvine Partners LLPAndrew KeithCalvine Partners LLP14 その他のアナリストを表示
お知らせ • Aug 06Basilea Pharmaceutica Ltd Receives Additional Funding to Continue Development of Novel Antibiotic Ceftibuten-Ledaborbactam EtzadroxilBasilea Pharmaceutica Ltd. has been awarded an additional USD 5.4 million of funding by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, to continue the development of the novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. After this additional funding of USD 5.4 million, a total of USD 30.8 million of funding has been awarded to Basilea by BARDA. The contract has the potential to provide a total of up to USD 172 million of non-dilutive funding, of which approximately USD 14 million relate to the period prior to novation of the contract to Basilea. Many Gram-negative bacteria express enzymes such as extended spectrum beta-lactamases (ESBL) that confer resistance against commonly used antibiotics. Beta-lactamase inhibitors block these enzymes and restore the activity of beta-lactam antibiotics against initially resistant Gram-negative bacteria, therefore BL/BLI combinations are an important addition to the armamentarium for the treatment of infections caused by multidrug-resistant bacterial pathogens. Ledaborbactam etzadroxil is the orally bioavailable prodrug of ledaborbactam, a novel broad-spectrum boronic acid beta-lactamase inhibitor, which is being developed in combination with ceftibuten, an oral cephalosporin antibiotic, which is approved in the US for the treatment of upper and lower respiratory tract infections and for urinary tract infections outside the US. In vitro and in vivo studies demonstrated that ledaborbactam etzadroxil restores the activity of ceftibuten against strains of Enterobacterales expressing Ambler class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and class A and D carbapenemases (KPC and OXA-48, respectively) as well as multidrug-resistant (MDR) Enterobacterales. Ceftibuten-ledaborbactam etzadroxil has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the US Food and Drug Administration (FDA) for cUTI and uncomplicated urinary tract infections. Ceftibuten-ledaborbactam etzadroxil is an investigational drug and is not yet approved in any country for commercial use. Complicated UTIs, which include pyelonephritis (kidney infections), are defined as urinary tract infections ascending from the bladder accompanied by local and systemic signs and symptoms and are one of the most common bacterial infections in hospital and community settings. Increasing resistance of bacteria causing complicated urinary tract infections has led to limited availability of effective oral antibiotic treatment options. Currently, there are no approved oral beta-lactam or beta-lactam/beta-lactamase inhibitor combinations that are effective against Enterobacterales expressing Ambler class A ESBLs, class C cephalosporinases, and class A & D serine carbapenemases (KPC and OXA-48).
お知らせ • Jul 29Basilea Receives USD 30 Million Funding Under Existing BARDA Agreement for Advancing Phase 3 Development of Novel Antifungal FosmanogepixBasilea Pharmaceutica Ltd, Allschwil announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), awarded USD 30 million in additional funding to Basilea after meeting its prespecified enrollment milestone. The additional funding will continue to advance Basilea’s ongoing phase 3 program for the novel antifungal, fosmanogepix. The commitment is made under the “Other Transaction Agreement” (OTA, agreement number 75A50124C00033). The new tranche of USD 30 million comes in addition to the USD 93 million already committed by BARDA since the signing of the OTA in September 2024. BARDA’s financial contribution is about 60% of the total costs of the supported projects, fosmanogepix and BAL2062, including clinical and regulatory activities, over the term of the OTA, which could provide a total potential non-dilutive funding of up to approximately USD 268 million over up to 12 years, if all additional options to extend the contract are exercised by BARDA. Fosmanogepix is a first-in-class clinical-stage broad-spectrum antifungal. It has a novel mechanism of action and its active moiety has shown activity against common species of Candida and Aspergillus, including multi-drug-resistant strains, such as Candida auris and Candida glabrata, as well as rare difficult-to-treat molds including Fusarium spp., Scedosporium spp., and some fungi from the Mucorales order. Fosmanogepix intravenous and oral formulations have been evaluated in clinical phase 2 studies for the treatment of patients with Candidemia, including Candida auris infections, and invasive mold infections. The FAST study, a phase 3 study evaluating fosmanogepix in the treatment of adult patients with candidemia and/or invasive candidiasis and the FORWARD study, a phase 3 study, in the treatment of adult patients with invasive mold infections, are ongoing. Fosmanogepix has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration for a number of indications, and is designated as a Qualified Infectious Disease Product (QIDP). BAL2062 is a first-in-class clinical-stage antifungal, derived from a natural product, and has demonstrated fungicidal activity against clinically important molds such as Aspergillus spp., including azole-resistant strains. Safety and tolerability have been demonstrated in a previously completed phase 1 study with single and multiple ascending intravenous (i.v.) doses. The drug candidate has Qualified Infectious Disease Product (QIDP), Orphan Drug and Fast Track designation from the US Food and Drug Administration (FDA) for invasive aspergillosis.
お知らせ • May 28Basilea Pharmaceutica Ltd Receives Additional USD 13.3 Million From BARDA To Continue Development Of Novel Antibiotic Ceftibuten-Ledaborbactam EtzadroxilBasilea Pharmaceutica Ltd, Allschwil announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, awarded USD 13.3 million to Basilea to continue the development of Basilea’s novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. After the current tranche of USD 13.3 million, a total of USD 25 million have been committed by BARDA. The contract could provide up to USD 133 million of additional non-dilutive funding. Many Gram-negative bacteria express enzymes such as extended spectrum beta-lactamases (ESBL) that confer resistance against commonly used antibiotics. Beta-lactamase inhibitors block these enzymes and restore the activity of beta-lactam antibiotics against initially resistant Gram-negative bacteria, therefore BL/BLI combinations are an important addition to the armamentarium for the treatment of infections caused by multidrug-resistant bacterial pathogens. Ledaborbactam etzadroxil is the orally bioavailable prodrug of ledaborbactam, a novel broad-spectrum boronic acid beta-lactamase inhibitor, which is being developed in combination with ceftibuten, an oral cephalosporin antibiotic, which is approved in the US for the treatment of upper and lower respiratory tract infections and for urinary tract infections outside the US. In vitro and in vivo studies demonstrated that ledaborbactam etzadroxil restores the activity of ceftibuten against strains of Enterobacterales expressing Ambler class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and class A and D carbapenemases (KPC and OXA-48, respectively) as well as multidrug-resistant (MDR) Enterobacterales. Ceftibuten-ledaborbactam etzadroxil has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the US Food and Drug Administration (FDA) for cUTI and uncomplicated urinary tract infections. Ceftibuten-ledaborbactam etzadroxil is an investigational drug and is not yet approved in any country for commercial use. Complicated UTIs, which include pyelonephritis (kidney infections), are defined as urinary tract infections ascending from the bladder accompanied by local and systemic signs and symptoms and are one of the most common bacterial infections in hospital and community settings. Increasing resistance of bacteria causing complicated urinary tract infections has led to limited availability of effective oral antibiotic treatment options. Currently, there are no approved oral beta-lactam or beta-lactam/beta-lactamase inhibitor combinations that are effective against Enterobacterales expressing Ambler class A ESBLs, class C cephalosporinases, and class A & D serine carbapenemases (KPC and OXA-48).
お知らせ • Apr 27Basilea Pharmaceutica AG to Report First Half, 2026 Results on Aug 18, 2026Basilea Pharmaceutica AG announced that they will report first half, 2026 results on Aug 18, 2026
お知らせ • Apr 17Basilea Pharmaceutica AG Approves Board and Committee AppointmentsBasilea Pharmaceutica Ltd. at its annual general meeting held on April 15, 2026, approved election of Dr. Naseem Amin and Ms. Anne Whitaker as new members of the board of directors. In addition, Mr. Kruimer, Dr. Onetto and Ms. Anne Whitaker were appointed as members of the compensation committee. The term of all board members lasts until the AGM 2027.
お知らせ • Apr 11Basilea Pharmaceutica Ltd Announces Additional Funding for Clinical Development of Antibiotic BAL2420Basilea Pharmaceutica Ltd, Allschwil announced that it was awarded an additional USD 6 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products. The additional non-dilutive funding will support the first-in-human phase 1 clinical study of Basilea’s novel antibiotic BAL2420 (LptA inhibitor) and related activities. The phase 1 study has already been initiated, with the first subject dosed in March 2026. BAL2420 belongs to one of the very few novel classes of antibiotics in clinical development. It is targeting LptA, which is part of the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. LptA inhibitors have shown potent and rapid bactericidal activity in vitro and in vivo against Gram-negative bacteria of the Enterobacteriaceae family, such as E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin, an antibiotic regarded as last-resort therapy. The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have identified Enterobacteriaceae, including carbapenem-resistant strains, as high priority pathogens for which new and effective antibiotic treatments are urgently needed. CARB-X has supported the development of BAL2420 since 2020, advancing the project from the hit-to-lead stage to the first-in-human study. Research reported in this publication is supported by CARB-X. CARB-X is funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) under agreement number 75A50122C00028 and by awards from Wellcome (WT224842), the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Gates Foundation, Germany’s Federal Ministry of Research, Technology and Space (BMFTR), the Novo Nordisk Foundation, Italy’s Ministry of Economy and Finance (MEF), Japan’s Ministry of Health, the European Commission’s DG Health Emergency Preparedness and Response Authority (DG HERA), and KfW Development Bank. The U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in HHS, provides support in the form of in-kind services through access to a suite of preclinical services for product development. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or its funders.
お知らせ • Aug 06Basilea Pharmaceutica Ltd Receives Additional Funding to Continue Development of Novel Antibiotic Ceftibuten-Ledaborbactam EtzadroxilBasilea Pharmaceutica Ltd. has been awarded an additional USD 5.4 million of funding by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, to continue the development of the novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. After this additional funding of USD 5.4 million, a total of USD 30.8 million of funding has been awarded to Basilea by BARDA. The contract has the potential to provide a total of up to USD 172 million of non-dilutive funding, of which approximately USD 14 million relate to the period prior to novation of the contract to Basilea. Many Gram-negative bacteria express enzymes such as extended spectrum beta-lactamases (ESBL) that confer resistance against commonly used antibiotics. Beta-lactamase inhibitors block these enzymes and restore the activity of beta-lactam antibiotics against initially resistant Gram-negative bacteria, therefore BL/BLI combinations are an important addition to the armamentarium for the treatment of infections caused by multidrug-resistant bacterial pathogens. Ledaborbactam etzadroxil is the orally bioavailable prodrug of ledaborbactam, a novel broad-spectrum boronic acid beta-lactamase inhibitor, which is being developed in combination with ceftibuten, an oral cephalosporin antibiotic, which is approved in the US for the treatment of upper and lower respiratory tract infections and for urinary tract infections outside the US. In vitro and in vivo studies demonstrated that ledaborbactam etzadroxil restores the activity of ceftibuten against strains of Enterobacterales expressing Ambler class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and class A and D carbapenemases (KPC and OXA-48, respectively) as well as multidrug-resistant (MDR) Enterobacterales. Ceftibuten-ledaborbactam etzadroxil has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the US Food and Drug Administration (FDA) for cUTI and uncomplicated urinary tract infections. Ceftibuten-ledaborbactam etzadroxil is an investigational drug and is not yet approved in any country for commercial use. Complicated UTIs, which include pyelonephritis (kidney infections), are defined as urinary tract infections ascending from the bladder accompanied by local and systemic signs and symptoms and are one of the most common bacterial infections in hospital and community settings. Increasing resistance of bacteria causing complicated urinary tract infections has led to limited availability of effective oral antibiotic treatment options. Currently, there are no approved oral beta-lactam or beta-lactam/beta-lactamase inhibitor combinations that are effective against Enterobacterales expressing Ambler class A ESBLs, class C cephalosporinases, and class A & D serine carbapenemases (KPC and OXA-48).
お知らせ • Jul 29Basilea Receives USD 30 Million Funding Under Existing BARDA Agreement for Advancing Phase 3 Development of Novel Antifungal FosmanogepixBasilea Pharmaceutica Ltd, Allschwil announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), awarded USD 30 million in additional funding to Basilea after meeting its prespecified enrollment milestone. The additional funding will continue to advance Basilea’s ongoing phase 3 program for the novel antifungal, fosmanogepix. The commitment is made under the “Other Transaction Agreement” (OTA, agreement number 75A50124C00033). The new tranche of USD 30 million comes in addition to the USD 93 million already committed by BARDA since the signing of the OTA in September 2024. BARDA’s financial contribution is about 60% of the total costs of the supported projects, fosmanogepix and BAL2062, including clinical and regulatory activities, over the term of the OTA, which could provide a total potential non-dilutive funding of up to approximately USD 268 million over up to 12 years, if all additional options to extend the contract are exercised by BARDA. Fosmanogepix is a first-in-class clinical-stage broad-spectrum antifungal. It has a novel mechanism of action and its active moiety has shown activity against common species of Candida and Aspergillus, including multi-drug-resistant strains, such as Candida auris and Candida glabrata, as well as rare difficult-to-treat molds including Fusarium spp., Scedosporium spp., and some fungi from the Mucorales order. Fosmanogepix intravenous and oral formulations have been evaluated in clinical phase 2 studies for the treatment of patients with Candidemia, including Candida auris infections, and invasive mold infections. The FAST study, a phase 3 study evaluating fosmanogepix in the treatment of adult patients with candidemia and/or invasive candidiasis and the FORWARD study, a phase 3 study, in the treatment of adult patients with invasive mold infections, are ongoing. Fosmanogepix has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration for a number of indications, and is designated as a Qualified Infectious Disease Product (QIDP). BAL2062 is a first-in-class clinical-stage antifungal, derived from a natural product, and has demonstrated fungicidal activity against clinically important molds such as Aspergillus spp., including azole-resistant strains. Safety and tolerability have been demonstrated in a previously completed phase 1 study with single and multiple ascending intravenous (i.v.) doses. The drug candidate has Qualified Infectious Disease Product (QIDP), Orphan Drug and Fast Track designation from the US Food and Drug Administration (FDA) for invasive aspergillosis.
お知らせ • May 28Basilea Pharmaceutica Ltd Receives Additional USD 13.3 Million From BARDA To Continue Development Of Novel Antibiotic Ceftibuten-Ledaborbactam EtzadroxilBasilea Pharmaceutica Ltd, Allschwil announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services, awarded USD 13.3 million to Basilea to continue the development of Basilea’s novel oral antibiotic ceftibuten-ledaborbactam etzadroxil, a beta-lactam/beta-lactamase inhibitor (BL/BLI) combination, for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis. After the current tranche of USD 13.3 million, a total of USD 25 million have been committed by BARDA. The contract could provide up to USD 133 million of additional non-dilutive funding. Many Gram-negative bacteria express enzymes such as extended spectrum beta-lactamases (ESBL) that confer resistance against commonly used antibiotics. Beta-lactamase inhibitors block these enzymes and restore the activity of beta-lactam antibiotics against initially resistant Gram-negative bacteria, therefore BL/BLI combinations are an important addition to the armamentarium for the treatment of infections caused by multidrug-resistant bacterial pathogens. Ledaborbactam etzadroxil is the orally bioavailable prodrug of ledaborbactam, a novel broad-spectrum boronic acid beta-lactamase inhibitor, which is being developed in combination with ceftibuten, an oral cephalosporin antibiotic, which is approved in the US for the treatment of upper and lower respiratory tract infections and for urinary tract infections outside the US. In vitro and in vivo studies demonstrated that ledaborbactam etzadroxil restores the activity of ceftibuten against strains of Enterobacterales expressing Ambler class A extended spectrum beta-lactamases (ESBLs), class C cephalosporinases, and class A and D carbapenemases (KPC and OXA-48, respectively) as well as multidrug-resistant (MDR) Enterobacterales. Ceftibuten-ledaborbactam etzadroxil has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the US Food and Drug Administration (FDA) for cUTI and uncomplicated urinary tract infections. Ceftibuten-ledaborbactam etzadroxil is an investigational drug and is not yet approved in any country for commercial use. Complicated UTIs, which include pyelonephritis (kidney infections), are defined as urinary tract infections ascending from the bladder accompanied by local and systemic signs and symptoms and are one of the most common bacterial infections in hospital and community settings. Increasing resistance of bacteria causing complicated urinary tract infections has led to limited availability of effective oral antibiotic treatment options. Currently, there are no approved oral beta-lactam or beta-lactam/beta-lactamase inhibitor combinations that are effective against Enterobacterales expressing Ambler class A ESBLs, class C cephalosporinases, and class A & D serine carbapenemases (KPC and OXA-48).
お知らせ • Apr 27Basilea Pharmaceutica AG to Report First Half, 2026 Results on Aug 18, 2026Basilea Pharmaceutica AG announced that they will report first half, 2026 results on Aug 18, 2026
お知らせ • Apr 17Basilea Pharmaceutica AG Approves Board and Committee AppointmentsBasilea Pharmaceutica Ltd. at its annual general meeting held on April 15, 2026, approved election of Dr. Naseem Amin and Ms. Anne Whitaker as new members of the board of directors. In addition, Mr. Kruimer, Dr. Onetto and Ms. Anne Whitaker were appointed as members of the compensation committee. The term of all board members lasts until the AGM 2027.
お知らせ • Apr 11Basilea Pharmaceutica Ltd Announces Additional Funding for Clinical Development of Antibiotic BAL2420Basilea Pharmaceutica Ltd, Allschwil announced that it was awarded an additional USD 6 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products. The additional non-dilutive funding will support the first-in-human phase 1 clinical study of Basilea’s novel antibiotic BAL2420 (LptA inhibitor) and related activities. The phase 1 study has already been initiated, with the first subject dosed in March 2026. BAL2420 belongs to one of the very few novel classes of antibiotics in clinical development. It is targeting LptA, which is part of the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. LptA inhibitors have shown potent and rapid bactericidal activity in vitro and in vivo against Gram-negative bacteria of the Enterobacteriaceae family, such as E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin, an antibiotic regarded as last-resort therapy. The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have identified Enterobacteriaceae, including carbapenem-resistant strains, as high priority pathogens for which new and effective antibiotic treatments are urgently needed. CARB-X has supported the development of BAL2420 since 2020, advancing the project from the hit-to-lead stage to the first-in-human study. Research reported in this publication is supported by CARB-X. CARB-X is funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA) under agreement number 75A50122C00028 and by awards from Wellcome (WT224842), the UK Department of Health and Social Care’s Global Antimicrobial Resistance Innovation Fund (GAMRIF), the Gates Foundation, Germany’s Federal Ministry of Research, Technology and Space (BMFTR), the Novo Nordisk Foundation, Italy’s Ministry of Economy and Finance (MEF), Japan’s Ministry of Health, the European Commission’s DG Health Emergency Preparedness and Response Authority (DG HERA), and KfW Development Bank. The U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in HHS, provides support in the form of in-kind services through access to a suite of preclinical services for product development. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or its funders.
お知らせ • Mar 26Basilea Pharmaceutica AG, Annual General Meeting, Apr 15, 2026Basilea Pharmaceutica AG, Annual General Meeting, Apr 15, 2026, at 14:00 W. Europe Standard Time.
お知らせ • Mar 23Basilea Pharmaceutica Ltd Announces Start Of First-In-Human Study Of Novel Antibiotic BAL2420Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced the dosing of the first healthy volunteer in the first-in-human phase 1 study of BAL2420, evaluating the safety, tolerability and pharmacokinetics of this lipopolysaccharide transport protein A (LptA) inhibitor. BAL2420 belongs to a novel class of antibiotics. It targets LptA, which is part of the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. LptA inhibitors have shown potent and rapid bactericidal activity in vitro and in vivo against Gram-negative bacteria of the Enterobacteriaceae family, such as E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin, an antibiotic regarded as last-resort therapy. The Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have identified Enterobacteriaceae, including carbapenem-resistant strains, as high priority pathogens for which new and effective antibiotic treatments are urgently needed. This single-center, randomized, dose-escalation, double-blind and placebo-controlled phase 1 study assesses intravenous administration of BAL2420 using a single- and multiple-ascending dose study design. Data from this study will support the further clinical development of BAL2420 as a potential treatment option for serious infections caused by Gram-negative bacteria, including multidrug-resistant bacteria. CARB-X has supported the development of BAL2420 since 2020, advancing the project from the Hit-to-Lead stage to the first-in-human study. CARB-X’s funding for this project is provided by federal funds from the US Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; under agreement number: 75A50122C00028, and by awards from Wellcome (WT224842) and Germany’s Federal Ministry of Research, Technology and Space (BMFTR). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders.
お知らせ • Feb 18+ 1 more updateBasilea Pharmaceutica AG Provides Earnings Guidance for the Full Year 2026Basilea Pharmaceutica AG provided earnings guidance for the full year 2026. For the year, the company expects total revenue of ~10% increase. Operating profit of ~20% increase.
